阿伐曲泊帕,一种口服血小板生成素受体激动剂:两项双盲、剂量递增、安慰剂对照的1期研究结果
两项在健康成人中开展的双盲、剂量递增、安慰剂对照1期研究评估了阿伐曲泊帕的安全性、耐受性、药代动力学及对血小板计数的影响。单次给药研究(N=63)和多次给药研究(N=29)均未发生严重不良事件、剂量限制性毒性、死亡、导致退出的不良事件、血栓或肝功能异常。阿伐曲泊帕峰浓度和暴露量随剂量成比例增加,半衰期为18-21小时且与剂量无关,支持每日一次给药;血小板计数升高始于给药后3-5天,每日20 mg在13-16天后最大变化超过基线370×10^9/L。
要点
- 两项双盲、剂量递增、安慰剂对照1期研究在健康成人中评估阿伐曲泊帕。
- 未发生严重不良事件、剂量限制性毒性、死亡、导致退出的不良事件、血栓或肝功能异常。
- 峰浓度和暴露量随剂量成比例增加,半衰期18-21小时且与剂量无关,支持每日一次给药。
核心结论
- 这些数据支持继续开发阿伐曲泊帕用于治疗其他血小板减少症,并为血液科医生使用这种新型血小板生成素受体激动剂提供重要指导。
研究设计与样本
- 两项双盲、剂量递增、安慰剂对照1期研究在健康成人中开展,评估阿伐曲泊帕的安全性、耐受性、药代动力学及对血小板计数的影响。
- 单次给药研究(N=63)按2:1随机分配至阿伐曲泊帕(1、3、10、20、50、75和100 mg)或安慰剂。
- 多次给药研究(N=29)按2:1随机分配至阿伐曲泊帕(3、10和20 mg)或安慰剂,每日一次,持续14天。
主要发现
- 未发生严重不良事件、剂量限制性毒性、死亡、导致退出的不良事件、血栓或肝功能异常。
- 两项研究中,阿伐曲泊帕峰浓度和暴露量随剂量成比例增加;半衰期为18-21小时且与剂量无关,支持每日一次给药。
- 对血小板计数的影响取决于剂量、浓度和治疗持续时间;血小板计数升高始于给药后3-5天。
- 每日20 mg在13-16天后最大变化超过基线370×10^9/L。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Avatrombopag is an oral thrombopoietin receptor agonist that has been recently approved for treating thrombocytopenia in chronic liver disease patients needing invasive procedures. Clinical trials supporting this new treatment were guided by two double-blind, dose-rising, placebo-controlled Phase 1 studies in healthy adults reported here that assessed safety, tolerability and pharmacokinetic profile of avatrombopag, and its effect on platelet counts. Subjects were randomised (2:1) in the single-dose study (N = 63) to avatrombopag (1, 3, 10, 20, 50, 75 and 100 mg) or placebo, and in the multiple-dose study (N = 29) to avatrombopag (3, 10 and 20 mg) or placebo daily for 14 days. There were no serious adverse events (AEs), dose-limiting toxicities, deaths, AEs causing withdrawal, thromboses or liver function abnormalities. In both studies, avatrombopag peak concentration and exposure increased proportionally relative to dose; half-life was 18-21 h and independent of dose, supporting once-daily dosing. Effects on platelet counts depended on dose, concentration and treatment duration. Platelet count increases began 3-5 days post-administration, with maximum changes of >370 × 109 /l over baseline with 20 mg daily after 13-16 days. These data support continued development of avatrombopag for treatment of other thrombocytopenic conditions and provide important guidance for the haematologist in the use of this new thrombopoietin receptor agonist.
引用
- Kuter DJ, Allen LF. Avatrombopag, an oral thrombopoietin receptor agonist: results of two double-blind, dose-rising, placebo-controlled Phase 1 studies. Br J Haematol. 2018. PMID: 30203841. doi:10.1111/bjh.15574
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。